J. Mendiboure

发表

Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study).

B. Chauffert, T. Conroy, M. Ychou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft‐tissue sarcoma patients in the competing risks setting

J. Blay, P. Terrier, S. Bonvalot, 2014, Cancer.

A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial.

T. Greten, E. Assenat, T. Trarbach, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer.

D. Planchard, J. Soria, R. Pirker, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

M. Loriot, P. Beaune, D. Trégouët, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunogenic death of colon cancer cells treated with oxaliplatin

J. Pignon, L. Zitvogel, O. Kepp, 2010, Oncogene.

MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.

Jane J. Sohn, A. Schetter, G. Giaccone, 2010, Cancer research.

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

Pierre Michel, Bernard Denis, Pierre-Luc Etienne, 2011, The Lancet. Oncology.

Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study.

B. Bui, J. Coindre, S. Mathoulin-Pélissier, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer

P. Hainaut, E. Brambilla, S. Lantuejoul, 2014, Molecular oncology.

MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

H. Popper, D. Planchard, J. Soria, 2010, Clinical Cancer Research.

Smooth muscle differentiation identifies two classes of poorly differentiated pleomorphic sarcomas with distinct outcome

F. Chibon, Gaëlle Pérot, V. Brouste, 2014, Modern Pathology.

Long‐term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow‐up

J. Blay, P. Terrier, A. Cesne, 2014, Cancer.

Hyperthermic Pelvic Perfusion With Tumor Necrosis Factor-&agr; for Locally Advanced Cancers: Encouraging Results of a Phase II Study

S. Bonvalot, A. Eggermont, A. Paci, 2012, Annals of surgery.

MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer.

D. Planchard, J. Soria, R. Pirker, 2009, Journal of Clinical Oncology.